If I may, Mr. Chair, the policy changes that we've seen in other country's militaries—in the United States, in the United Kingdom—they have generally followed or have reflected regulatory re-evaluation of the drug.
In the United States, around the time that the U.S. military formally declared it a drug of last resort, the FDA was adding the boxed warning to the medication. Similarly, in the U.K., some years ago a similar warning was added across Europe and now the Ministry of Defence has declared it a drug of last resort.
I do think that any substantive policy re-evaluation here in Canada should be informed by an updated mefloquine product label. The Canadian product label for mefloquine does not state that the drug can cause permanent effects. The Canadian drug label does not state, as it does in other countries, that you should immediately stop taking the drug at the onset of nightmares or abnormal dreams.
I would argue that an update to the label should probably precede a policy re-evaluation. That being said, if the Department of National Defence and others feel there is sufficient information, even in the absence of that update, to warrant action, then of course adopting a policy that reflects that seen in other countries would, in my opinion, be entirely reasonable.